Zur Kurzanzeige

Development of a Rhesus macaque engineered heart muscle model from pluripotent stem cells

dc.contributor.advisorZimmermann, Wolfram-Hubertus Prof. Dr.
dc.contributor.authorGolat, Brian
dc.date.accessioned2017-06-13T09:05:43Z
dc.date.available2017-06-13T09:05:43Z
dc.date.issued2017-06-13
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-0023-3E73-D
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-6342
dc.language.isoengde
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610
dc.titleDevelopment of a Rhesus macaque engineered heart muscle model from pluripotent stem cellsde
dc.typedoctoralThesisde
dc.contributor.refereeBehr, Rüdiger Prof. Dr.
dc.date.examination2017-05-15
dc.description.abstractengMyocardial infarction is the leading cause of death globally. Remuscularization of the heart with stem cell based treatments is one potential approach to heart repair which is presently being tested. Proof-of-concept studies, mostly in rodent models, have shown promising results. Nevertheless, to be therapeutically relevant it is essential to test evolving therapeutic strategies in large animal models with high predictive value as to clinical outcome. Unfortunately, a lack of pluripotent stem cell models available in most animal species used for late stage preclinical testing creates a major challenge. Non-human primate models, and here in particular macaque models, appear to be an exception with the documentation of successful derivation of stable pluripotent stem cell models by several groups. In this dissertation the following hypotheses were tested: (1) induced pluripotent stem (iPS) cells from Rhesus macaque (Macaca mulatta) can be used to derive cardiomyocytes, (2) Rhesus macaque iPS-derived cardiomyocytes can be used to construct engineered heart muscle (EHM) with contractile properties similar to observations in human EHM, (3) parthenogenetic pluripotent stem cells can be derived from Rhesus macaque unfertilized oocytes as an alternative source of pluripotent stem cells with distinct advantages regarding immunological matching. Two available Rhesus iPS cell lines, either generated by lentiviral or Sendai viral transduction of reprogramming factors, were subjected to directed differentiation using a similar protocol as recently established for human pluripotent stem cells. High cardiomyocyte yield and purity could be achieved. Cardiomyocytes differentiated from both iPS cell lines could be used to generate EHM with similar contractile properties. Evidence for successful induction of parthenogenesis was obtained. Collectively, this dissertation provides the methodological groundwork for the implementation of Rhesus macaque pluripotent stem cell derived EHMs for pivotal late stage preclinical studies of tissue engineered heart failure repair.de
dc.contributor.coRefereeWalter, Lutz Prof. Dr.
dc.contributor.thirdRefereeDressel, Ralf Prof. Dr.
dc.contributor.thirdRefereeLuther, Stefan Prof. Dr.
dc.contributor.thirdRefereeJohnsen, Steven Prof. Dr.
dc.subject.engRhesus macaquede
dc.subject.engEHMde
dc.subject.engengineered heart musclede
dc.subject.engstem cellsde
dc.subject.engheart modelde
dc.subject.engtissue engineeringde
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-0023-3E73-D-6
dc.affiliation.instituteMedizinische Fakultät
dc.subject.gokfullMedizin (PPN619874732)de
dc.subject.gokfullPharmakologie / Toxikologie / Pharmakotherapie - Allgemein- und Gesamtdarstellungen (PPN61987550X)de
dc.identifier.ppn890230560


Dateien

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige